15 April 2024, IXICO plc (AIM: IXI), London, UK, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials.
Read moreLammert Albers, Chief Commercial Officer of the Global Alzheimer's Platform Foundation talks with John Dwyer, President of the foundation, and our Chief Scientific Officer, Robin Wolz about the impact of this study diversity on current and future research and the opportunities at hand at the upcoming CTAD Clinical Trials on Alzheimer's Disease 2023 conference in Boston.
Read moreNew York, NY / London, UK, July, 12th 2023; The Huntington’s Disease Imaging Harmonization (HD-IH) Consortium, founded last year to conduct an unprecedented harmonization analysis of more than 6,000 participant-visit magnetic resonance images (MRIs) acquired from over 2,000 research participants, has now completed the initial phase and secured the necessary funding commitment to complete the…
Read more